Sometimes, treatments used in conjunction with each other can confer benefits for patients. According to the Cancer Network, for example, treating platinum-resistant ovarian cancer using nemvaleukin alfa and pembrolizumab (Keytruda)…
September will soon come to a close, but did you know that this month is also Ovarian Cancer Awareness Month? According to a story from MSN, Michelle Barrenechea, an EMT…
Recent data published in Gynecologic Oncology has confirmed the safety of olaparib for the treatment of advanced, BRCA-mutated, newly diagnosed ovarian cancer. This data came from the Phase 3 SOLO1 trial,…
Normally, Fast Track is an FDA process designed to facilitate and expedite the development and review of drugs or biologics intended to treat rare or serious conditions. Recently, Healio…
Unfortunately, recurrent ovarian cancer can be difficult to treat and often comes with a poor prognosis. However, according to a news release from biopharmaceutical company IMV Inc. ("IMV"), the company…
BeiGene has just announced that China has given conditional approval to Pamiparib, a PARP inhibitor used as a therapy for BRCA associated ovarian cancer, fallopian tube cancer, and primary peritoneal…
Poly ADP ribose polymerase (PARP) inhibitors are targeted cancer therapies which block PARP, an enzyme. Normally, PARP plays a role in DNA repair. Thus, inhibiting PARP prevents cancer cells from…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
